

Dexmedetomidine as an Adjuvant to Bupivacaine in Supraclavicular Brachial Plexus Block



Medical Science

KEYWORDS : Supraclavicular brachial block, dexmedetomidine, analgesia, sedation

Dr. G. H. MEGHA

Assistant Professor Department Of Anaesthesiology, Bmch&Rc

Dr. SANJEEV G M

PROF and HOD, Department of anaesthesia, BMCH&RC.

ABSTRACT

Alpha-2 agonists are mixed with local anaesthetic agents to extend the duration of spinal, extradural and peripheral nerve blocks. We studied the effect of dexmedetomidine as an adjuvant to bupivacaine in brachial plexus block on onset and duration of sensory and motor block, duration of analgesia, level of sedation, perioperative hemodynamic parameters and complications.

Methods: forty patients of ASA I and ASA II scheduled for upper limb surgery were included in double blind randomised comparison of inj. Dexmedetomidine and inj. Normal saline. We divided patients in two groups. Group A patients were given inj dexmedetomidine 50 microgm (0.5ml) and group B patients were given inj normal saline in brachial plexus block as adjuvant to 30 ml of local anaesthetic solution containing 14 ml of lidocaine with adrenaline and 16ml bupivacaine. We recorded time of onset and duration of sensory and motor block, level of sedation, duration of analgesia, hemodynamic changes and side effects in both groups.

Results: mean time to onset of sensory block was 5.42±1.39 min in group A and 8.34± 1.35 min group B and that of motor block was 11.1± 2.6min in group A and 18.0± 2.9min in group B. Total duration of sensory block was 730.15±78.27min in group A and 360.62±61.7min in group B and that of motor block was 616.2± 54.46min in group A and 288.4± 54.26min in group B. Duration of analgesia was 970.36 ± 80.7 min in group A and 300±40.31 min in group B.

Conclusion: addition of 50 microgm of inj dexmedetomidine to bupivacaine in brachial plexus block shortens onset and prolongs duration of sensory and motor block, prolongs duration of analgesia and decreases intraoperative requirement of sedatives.

Introduction

Supraclavicular brachial plexus block via Winnie's approach is a very popular mode of anaesthesia for various upper limb surgeries. This approach is attractive due to its effectiveness in terms of cost and performance, margin of safety along with good post-operative analgesia. Supraclavicular route for brachial plexus block was first introduced by Kullenkampff in 1911 which was later modified as Winnie block¹. The brachial plexus are blocked at the level of distal trunk and proximal division where they are compact in structure so just 30ml volume of local anaesthetic solution is adequate in an adult person. It achieves ideal operating conditions for forearm surgeries².

Dexmedetomidine belongs to imidazole subclass of α_2 agonists². Drug which has $\alpha_2:\alpha_1$ selectivity of 1600:1 which is 8 times that of clonidine. It has central action of sedation, hypnosis and analgesia by acting on locus caeruleus of brain stem. Several hypothesized mechanisms of action have been suggested to explain the analgesic effect of α_2 -adrenoceptor agonists. Some of these include vasoconstriction around the injection site, direct suppression of impulse propagation through neurons as a result of a complex interaction with axonal ion channels or receptors, local release of enkephalin-like substances, a decrease in localized inflammatory mediators and an increase in anti-inflammatory cytokines through an α_2 -adrenoceptor-mediated mechanism³. It also has supraspinal analgesic action via noradrenergic neurons by hyperpolarisation. It inhibits norepinephrine release in descending medullospinal tract. Study was undertaken to compare inj. Dexmedetomidine 50 microgm (0.5ml) and inj. normal saline 0.5ml along with 30ml local anaesthetic in supraclavicular brachial plexus block for elective forearm surgery.

MATERIALS AND METHODS:

After obtaining approval from the institutional ethical committee, 40 patients of ASA I and ASA II scheduled for elective forearm surgery were included in double blind randomised comparison of inj. Dexmedetomidine 50 microgm and inj. normal saline 0.5 ml.

INCLUSION CRITERIA

Age of patient-18-60 yrs
Weight of patient 50-60 kg
ASA grade 1 or 11

Exclusion criteria

Patients refusal
Allergy

Significant neurological diseases in upper limb coagulation disorders

The study was carried out in department of anaesthesia, BASSAVESWAR MEDICAL COLLEGE AND RESEARCH CENTER, CHITRADURGA during October 2012 to Dec 2013. Written and informed consent was taken after adequate explanation of procedure and complications.

All patients were assessed preoperatively and investigated. We divided patients randomly in two groups. Group A patients were given inj. Dexmedetomidine 50 microgm + inj. Bupivacaine 0.5% 16ml + inj. lignocaine 2% 14 ml in supraclavicular brachial plexus block and group B patients were given inj. normal saline 0.5 ml instead of inj. dexmedetomidine along with above 30 ml of local anaesthetic solution. All patients had fasted for minimum 6 hrs. Under all aseptic and antiseptic precautions, we gave supraclavicular brachial plexus block to the patient with peripheral nerve stimulator technique. Sensory block was assessed by atraumatic pin prick test. Motor block was assessed by using four point scale of 0 to 3. Analgesia was assessed by visual analogue scale scoring 1 to 10. We assessed various parameters at 5, 10, 15, 20, 25 and 30 min, and thereafter every 15 min for 2 hrs 30 min and then hourly till block effect has resolved. It includes sensory as well as motor block onset and duration along with duration of analgesia, level of sedation. Sedation score was assessed by modified Wilson sedation scale⁴, which has scoring from 1 to 4.

Score 1 - fully awake and oriented and follows verbal command

Score 2 - drowsy, eyes closed but arousable only to commands

Score 3 - eyes closed but arousable to mild physical stimulation (ear lobe tug)

Score 4 - eyes closed and unarousable to mild physical stimulation

Average sedation score was found to be 2.6 in Group A (dexmedetomidine) where as there was no sedation in Group B (normal saline) group. So inj. Midazolam 1mg, iv was given in almost all patients in group B that is of normal saline group. There was not a single episode of respiratory depression in either groups.

All the patients were monitored for vital parameters, sensory and motor blockade, level of sedation and complications if any.

Pulse rate, Blood pressure and SpO2 were recorded regularly throughout the period of study and post operatively till 24 hours. In our study the cardiovascular changes, i.e. heart rate and blood pressure changes were variable between both the groups. Vital parameters were monitored using multipara monitor. Pulse Rate, Systolic Blood Pressure, Diastolic Blood Pressure, Oxygen saturation were recorded at 0, 5, 10, 15, 30, 60, 120, 150 min and there after till the end of the surgery and at 1 hr, 4 hr, 6 hr, 12 hr and 18 hr.

After calculating MEAN and STANDARD DEVIATION of all parameters, patient's age and duration of surgery were analysed by student's unpaired 't'-test. Sex distribution and ASA gradings were analysed by chi-square test. Time for onset of adequate sensory block, duration of sensory and motor block were analysed by student's unpaired 't' test.

Sedation score was assessed by MODIFIED WILSON SCORE.10 Comparison of intraoperative complications like bradycardia and hypotension were analysed by Fisher exact test. The p-value was considered significant as shown below:

p > 0.05 not significant, p < 0.05 significant, p < 0.001 highly significant

Result: The incidence of hypotension and bradycardia was higher in group A as compared to group B but it was statistically insignificant (p>0.05). Incidence of sedation was there in group A in almost every patient as compared to group B and it was statistically significant. Incidence of respiratory depression was not present in any case of either group which was monitored by oxygen saturation (spo2). Hypotension was treated with adequate intravenous fluids and Inj. Mephentermine 6-12 mg i.v. and bradycardia was treated with Inj. Atropine 0.02 mg/kg i.v.

Table 1: Comparison Of Time Of Onset Of Complete Sensory And Motor Block

	Group A (dexmed)	Group B (normal saline)	P VALUE
Onset time for sensory block (min)	5.42± 1.39	8.24± 1.35	< 0.05
Onset time for motor block (min)	11.1± 2.6	18.0 ±2.9	< 0.05

Table 2: Demography

Parameters	Group A	Group B	p-Value
Age (Yrs) (Mean ± SD)	37.13 ± 14.14	37.2 ± 12.89	>0.05
Sex	Male 12 (73.3 %)	13 (66.67%)	>0.05
	Female 08 (26.7%)	07 (33.34%)	
ASA Grade	I 08 (60 %)	07 (56.67 %)	>0.05
	II 12 (40%)	13 (43.33%)	

COMPARISON OF BLOCK CHARACTERISTICS
3: Comparison Of Time Of Duration Of Block, Analgesia And Level Of Sedation

	GROUP A INJ. DEXMED	GROUP B Inj. N. saline	P value
SENSORY BLOCK(MIN)	730.15±78.27	360.62±61.7	<0.001
MOTOR BLOCK(MIN)	616.6±54.46	288.4±54.26 min	<0.001
ANALGESIA (MIN)	970.36 ± 80.7 min	300±40.31 min	<0.001
SEDATION SCORE(1-4)	2.4	1	

HEMODYNAMICS

Table 4: Comparison Of Mean Pulse Rate)

TIME (MIN)	GROUP A INJ. DEXMED (BEATS/MIN)	GROUP B INJ. N. SALINE (BEATS/MIN)	P VALUE
BASELINE	95.2 ± 4.24	94.2 ± 3.53	>0.05
5 MIN	91.4 ± 7.07	91.3 ± 2.82	>0.05
10 MIN	82.7 ± 4.24	84.3 ± 2.12	>0.05
15 MIN	70.1 ± 4.24	79.53 ± 3.70	<0.05
20 MIN	69.87 ± 3.89	78.13 ± 3.12	<0.05
25 MIN	66.7 ± 5.92	74.26 ± 4.24	<0.05
30 MIN	66 ± 5.65	79.2±3.53	<0.05
45 MIN	64.7±2.82	85.16±6.36	<0.05
60 MIN	66.7 ± 7.92	79.53 ± 0.70	<0.05
90 MIN	66 ± 5.16	70.43 ± 2.12	<0.05
120 MIN	67.7±2.88	74.26 ± 4.24	<0.05
150 MIN	68 ± 3.66	79.2±3.53	<0.05

Table 5: Comparison Of Intraoperative Mean Oxygen Saturation (Spo2) (%)

	Group A (DEXMED) (%)	Group B (normal saline) (%)	p value
BASAL	99.35±0.4	99.40±0.30	p > 0.05
5min	98.5±0.9	99.25±0.45	p > 0.05
10 mn	99.25±0.5	99.30±0.5	p > 0.05
15min	96.35±0.8	98.0±.25	p > 0.05
20min	96.4±0.6	98.35±0.5	p > 0.05
25min	96.4±0.7	97.75±0.5	p > 0.05
30min	96.7±0.5	97.5±0.4	p > 0.05
45min	98.35±0.4	98.35±0.5	p > 0.05
60min	98.75±0.8	98.40±0.25	p > 0.05
120min	98.35±0.5	99.0±0.4	p > 0.05
150min	99.25±0.5	99.30±0.5	p > 0.05

Table 6: Comparison Of Mean Systolic Bp

	GROUP A (mm Hg)	GROUP B (mm Hg)	p-VALUE
0 min	121±9.29	124.56 ± 1.41	>0.05
5 min	117±5.65	118.3±5.65	>0.05
10 min	111.23±3.53	121.2 ± 5.65	<0.05
15 min	103.46 ± 7.09	122.76 ± 8.48	<0.05
20 min	102.7 ± 5.7	110.4 ± 1.41	<0.05
25 min	106.9± 6.17	114.3 ± 6.36	<0.05
30 min	100.16 ± 1.41	118.43 ± 5.65	<0.05
45 min	103.86 ± 18.38	123.56 ± 12.02	<0.05
60 min	112.7 ± 7.7	120.4 ± 1.41	<0.05
90 min	110.9± 6.17	124.3 ± 6.36	<0.05
120 min	110.16 ± 1.41	128.43 ± 5.65	<0.05
150 min	113.86 ± 18.38	123.56 ± 12.02	<0.05

Table 7: Comparison Of Mean Diastolic

	Bp GROUP A (mm Hg)	GROUP B (mm Hg)	P VALUE
0 min	82.13±2.12	82.16±2.82	>0.05
5 min	77.66±4.24	80.03±1.41	>0.05

10 min	72.23±3.7	74.36±7.07	>0.05
15 min	69.33±4.84	79.53±0.70	<0.05
20 min	62.16±1.44	82.16±2.82	<0.05
25 min	65.83±9.10	80.03±1.41	<0.05
30 min	66.16±1.41	76.1±5.44	<0.05
45 min	64.23±6.10	78.83±2.70	<0.05
60 min	67.83±9.89	76.5±2.12	<0.05
120 min	71.3±12.72	78.63±9.19	<0.05
150 min	75.63±12.72	77.13±6.36	>0.05

Table 8: Postoperative Changes In Mean Systolic Bp

	GROUP A	GROUP B	
TIME	Systolic BP (mm Hg) (Mean±SD)	Systolic BP (mm Hg) (Mean±SD)	p value
IMMEDIATE POST-op	118.2±7.63	121.1±6.55	p>0.05
1 hr	118.9±6.14	121.5±6.04	p> 0.05
3 hr	120.2±5.59	121.3±5.99	p>0.05
6 hr	120.5±5.17	122±5.34	p>0.05
12 hr	120.4±5.42	121.3±5.39	p>0.05
15 hr	120.2±4.77	120±5.54	p>0.05
18 hr	120.8±3.42	122.3±3.39	p>0.05

Table 9 : Postoperative Changes In Mean Pulse Rate

	GROUP A (DEXMED)	GROUP B (N.SALINE)	
Time	Pulse rate (Mean±SD)	Pulse rate (Mean±SD)	p value
IMMEDIATE POST-OP	68.86±4.86	78.66±5.97	P<0.05
1 hr	70.33±4.1	74.8±4.8	p> 0.05
3 hr	72.47±3.86	72±5.04	p>0.05
6 hr	71.33±3.89	73.27±4.66	p>0.05
12 hr	76.53±3.95	75.13±5.53	p>0.05
15 hrs	74.33± 4.16	74.81± 3.89	p>0.05
18 hrs	78.27 ±3.45	77.45± 4.58	p>0.05

Table 10 : Postoperative Changes In Mean Pulse Rate

	GROUP A (DEXMED)	GROUP B (N.SALINE)	
Time	Pulse rate (Mean±SD)	Pulse rate (Mean±SD)	p value
IMMEDIATE POST-OP	68.86±4.86	78.66±5.97	P<0.05
1 hr	70.33±4.1	74.8±4.8	p> 0.05
3 hr	72.47±3.86	72±5.04	p>0.05
6 hr	71.33±3.89	73.27±4.66	p>0.05
12 hr	76.53±3.95	75.13±5.53	p>0.05
15 hrs	74.33± 4.16	74.81± 3.89	p>0.05
18 hrs	78.27 ±3.45	77.45± 4.58	p>0.05

Table 11: Intra And Postoperative Complications

	GROUP A	GROUP B
Hypotension	2(10%)	0

Bradycardia	1(5%)	0
Nausea and vomiting	0	0
Sedation	18(90%)	0
Respiratory depression	0	0

Discussion: Demographic Data: The mean age of patients was 37.13 ± 14.14 years in Group A and 37.2 ± 12.89 years in Group B (p=NS). The ratio of Male to Female was 12:08 in Group A and 13:07 in Group B. The ASA I patients in group A were 08 and in group B were 07 while ASA II patients in group A were 12 and in group B were 13. It shows there is no statistical difference between two groups.

Blockade Characteristics : SENSORY BLOCK In our study time to initial onset of adequate level of sensory block was comparable in both groups. It was 5.42± 1.39 min in Group A and 8.24± 1.35min in Group B(p<0.05). Total duration of sensory block was 730.15± 78.27min in group A and 360.6 ±54.46 min in group B(p<0.001). It shows that inj. Dexmedetomidine had shorter onset of action and longer duration of sensory block than inj. Normal saline and it was statistically significant. Our study findings are comparable to previous studies conducted by A Esmaoglu et al in 20105. And Rachna Gandhi et al6. observed that there was no difference in onset of block when compared between dexmedetomidine and normal saline but there was significant prolongation of sensory and motor blockade with dexmedetomidine as compared to normal saline.

Motor Blockade; In our study time to initial onset of motor block was 11.1± 2.6 min in group A and 18.0 ±2.9 min in group B(p<0.05). Our results are comparable with study conducted by A Esmaoglu et al in 20105. It was comparable in both groups.

Total duration of motor block was 616.6±54.46 min inj dexmedetomidine group and 288.4±54.26 min in normal saline group (p<0.001) . It was comparable to previous studies done by A Esmaoglu et al in 20105. and by rachna Gandhi et al in 20126. our study results were also comparable to study done by sarita s. Swami et al8. who compared dexmedetomidine with clonidine and found dexmedetomidine has longer duration of motor blockade. Rachna Gandhi et al6. observed that there was no difference in onset of motor block when compared between dexmedetomidine and normal saline but there was significant prolongation of motor blockade with dexmedetomidine as compared to normal saline.

Analgesia: Rescue analgesic was given in the form of inj. Diclofenac 1-2 mg/kg slowly iv. When VAS score reached 4. Duration of analgesia was found to be 970.36±80.7 min in dexmedetomidine group and 300±40.31 min in normal saline group which was statistically significant. These results were comparable with previous studies done by A Esmaoglu et al5. in 2010 and sarita s. Swami et al8.

All previous studies also show that cardiovascular changes were variable between both the groups. There was bradycardia in one patient and hypotension in two patients in dexmedetomidine group which was statistically not significant and managed by iv fluids and inj atropine 0.6 mg iv. Our results are in consonance with A Esmaoglu et al5 in 2010. who observed variable cardiovascular changes between the two groups. Our results are also in consonance with Sarita s. Swami et al8. We observed that the cardiovascular changes, i.e. heart rate and blood pressure changes were variable between both the groups. Dexmedetomidine group has better hemodynamic stability compared to normal saline group.

Intraoperative and post operative complications:- In our study, intraoperative complications were not statistically significant in both groups. Incidence of Bradycardia was 5% (1/20) and that of hypotension was 10% (2/20) in dexmedetomidine group which was statistically not significant. Incidence of sedation was 90% (18/20) in dexmedetomidine and there was no seda-

tion in normal saline group and this was statistically significant. There was not a single episode of respiratory depression in both groups. None of the patients had other side effects.

Our study findings are comparable to previous studies done by A Esmoğlu et al.⁵ and Rachna Gandhi et al.⁶.

Conclusion : We concluded that by adding 50 microgm inj dexmedetomidine as an adjuvant in supraclavicular brachial plexus block along with inj bupivacaine 0.5% 16ml and inj lignocaine 2% 14ml.

- 1) Shortens onset of sensory and motor block.
- 2) Improves the block quality by increasing sensory and motor block duration
- 3) Increases the interval to first analgesic use
- 4) Provides better hemodynamic stability
- 5) Decreases the intraoperative requirement of sedative medications.

REFERENCE

1. Barash P. Clinical Anesthesia sixth edition. 20 | 2. Miller R. Miller's anesthesia seventh edition. vol 1/751 and vol 2/2538 | 3. Ammar AS, Mahmoud KM. Ultrasound-guided single injection infraclavicular brachial plexus block using bupivacaine alone or combined with dexmedetomidine for pain control in upper limb surgery: A prospective randomized controlled trial. *Saudi J Anaesth* 2012;6(2):109-14. doi: 10.4103/1658-354X.97021 | 4. Némethy M, Leonardo, Williams R. and Thomas J. J. Blanck, Assessing Sedation with Regional Anesthesia: Inter-Rater Agreement on a Modified Wilson Sedation Scale; *Anesth Analg* 2002;94:723-8 | 5. Esmoğlu A, Yegenoglu F. Dexmedetomidine added to levobupivacaine prolongs axillary brachial plexus block. *A & A* December 2010; 111: 1548-1551 | 6. Gandhi R, Shah A, Patel I. Use of dexmedetomidine along with bupivacaine for brachial plexus block. *National J Med Res.* (2012) | 7. Chad M., Mary A. Norat, B.S., John M. Palmisano B.S., and Lydic R. Perineural Administration of Dexmedetomidine in Combination with Bupivacaine Enhances Sensory and Motor Blockade in Sciatic Nerve Block without Inducing Neurotoxicity in the Rat. *Anesthesiology*. 2008 September; 109(3): 502-511. | 8. Swami SS, Keniya VM, Ladi SD, Rao R. *Indian J Anaesth.*; Comparison of dexmedetomidine and clonidine ($\alpha 2$ agonist drugs) as an adjuvant to local anaesthesia in supraclavicular brachial plexus block: A randomised double-blind prospective study; 2012 May; 56(3): 243-9 | 9. Rutkowska K, Knapik P, Misiolek H. ; The effect of dexmedetomidine sedation on brachial plexus block in patients with end-stage renal disease. 2009 Oct; 26(10): 851-5. | 10. Kaygusuz K, Kol I O , Duger C, Gursoy S, Ozturk H, Kayacan U, Aydin R, Mimaroglu R. Effects of Adding Dexmedetomidine to Levobupivacaine in Axillary Brachial Plexus Block; *Current Therapeutic Research* 2012; 73(3): 103-111 | 11. Rutkowska K; Knapik P; Misiolek H; Kucia H; Druzba K. The effect of intravenous dexmedetomidine on brachial plexus block in patients with end-stage renal failure: *European Journal of Anaesthesiology*; June 2006 - 23 : 124 | 12. Abdallah FW. and Brull R. Facilitatory effects of perineural dexmedetomidine on neuraxial and peripheral nerve block: a systematic review and meta-analysis; *Br. J. Anaesth.* (2013) doi: 10.1093/bja/aet066 |